UCB AND SANOFI-AVENTIS SIGN A CO-PROMOTION AGREEMENT FOR XYZAL IN THE UNITED STATES

UCB and sanofi-aventis announced that they have entered into an agreement to co-promote in the United States the prescription antihistamine medicine, Xyzal (levocetirizine dihydrochloride). Xyzal is a once-daily antihistamine which was first launched in Europe in 2001 and currently marketed in 49 countries around the world where it enjoys leadership position in key markets.

Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=166345)